Drugs Made In America Acquisition II Corp. (DMII) Assets (2024 - 2026)

Drugs Made In America Acquisition (DMII) has reported Assets for 3 consecutive years, with $514.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets changed N/A year-over-year to $514.1 million in Q2 2026; TTM through Jun 2026 was $514.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $505.0 million, up 365643.31% from the prior year.
• Assets was $514.1 million for Q2 2026 at Drugs Made In America Acquisition, up from $505.0 million in the prior quarter.
• Over five years, Assets peaked at $514.1 million in Q2 2026 and troughed at $138064.0 in Q4 2024.
• A 3-year average of $380.1 million and a median of $503.0 million in 2025 frame the typical range for Assets.
• The widest YoY moves for Assets: up 365643.31% in 2025, down 365643.31% in 2025.
• Over 3 years, Assets stood at $138064.0 in 2024, then surged by 365643.31% to $505.0 million in 2025, then climbed by 1.81% to $514.1 million in 2026.
• The last three Assets figures came in at $514.1 million (Q2 2026), $505.0 million (Q4 2025), and $501.0 million (Q3 2025), per Business Quant data.